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background: Despite the prolonged cancer-related survival in patients (pts) treated with anthracyclines, the treatment related cardiotoxicity 
remains a major concern. Even though there some experimental and clinical evidences supporting statins in anthracycline induced cardiotoxicity 
with adriamicin (doxorubicin), the data in the literature are still poor with epirubicin (farmorubicin), another anthracycline. The goal of this study 
was to assess the effect of continuous statin treatment (CST) on new-onset left ventricular dysfunction (LVD) +/- heart failure (HF) in pts with gastric 
cancer (GC) treated with epirubicin.
Methods: We analysed retrospectively starting with 01/JAN/2005 a number of 432 adult pts newly diagnosed with biopsy confirmed gastric 
cancer who underwent anthracycline based chemotherapy with epirubicin standard doses. The study group had 144 pts and received CST for usual 
indications. Their counterparts did not receive CST. The date of the GC confirmatory diagnosis was considered the study enter date. Demographically: 
mean age 57,5 +/-11,2 yrs., male gender predominence 72,3%. The primary outcome was incident LVD +/- HF, and the follow-up period 2,55 +/- 
1,68 yrs..
results: After propensity matching (1:2) the 144 pts receiving CST were combined with 288 controls. New onset LVD was diagnosed in 94 pts 
(25 in CST group vs 69 in their counterparts), including 33 pts with incident HF, 7 in CST group, 26 in their counterparts. The proportions in the two 
groups were 4,8611 and 9,0277, and the dispersions 0,046248 and 0,082127, respectively. Inside the CST group, 77 pts received atorvastatin, 52 
pts rosuvastatin, and 15 pts other statin. No significant differences were found among various statins; we also did not find any statistical differences 
between genders. 
conclusion: In our study, add-on therapy with statin was associated with lower risk for incident LVD +/- HF in pts with GC treated with epirubicin. 
This seems to be a class effect of statins. This finding warrants for further prospective investigation. Since the mechanism of anthracycline 
cardiotoxicity seems to be correlated with oxygen free radicals, the pleiotropic effects of statins may mitigate cardiotoxicity.
